Send me real-time posts from this site at my email
Zacks

Nu Skin (NUS) Q4 Earnings Beat Estimates, Revenues Down

Nu Skin Enterprises, Inc. NUS delivered fourth-quarter 2021 results, with the top and the bottom line beating the Zacks Consensus Estimate. However, revenues and earnings declined year over year.

Nu Skin highlighted that many of its Asian markets like Mainland China continue to face strict lockdowns as well as restrictions on in-person sales events and promotional activities. The South Korea region is benefiting from the adoption of social commerce. Further, the company is optimistic about its Nu Vision 2025 strategy. It is based around key strategic imperatives like EmpowerMe personalized beauty and wellness strategy with connected beauty devices, affiliate-powered social commerce business model and the expansion of the digital platform.

Nu Skin Enterprises, Inc. Price and EPS Surprise

 

Nu Skin Enterprises, Inc. price-eps-surprise | Nu Skin Enterprises, Inc. Quote

 

Q4 Highlights

Nu Skin reported quarterly earnings of $1.11 per share, down from $1.40 per share reported in the year-ago quarter. The metric beat the Zacks Consensus Estimate of 95 cents per share. Management highlighted that the bottom line benefited from gross margin and operational improvements.

Revenues of $673.4 million fell 10% year over year on a reported basis. Revenues included a negative impact of 2% from foreign currency fluctuations. On a constant-currency (cc) basis, revenues declined 8%. The top line surpassed the Zacks Consensus Estimate of $655.7 million. Management highlighted that it witnessed solid demand for the two most recent products — Beauty Focus Collagen+ and ageLOC Meta.

Sales leaders were down 13% year over year to 61,515. Nu Skin’s customer base dropped 12% to 1,367,559.

Gross profit of $499.7 million declined from $553.4 million reported in the year-ago quarter. The gross margin expanded year over year from 74% to 74.2%. Nu Skin business’ gross margin expanded to 77.9% from 76.5%.

Selling expenses declined from $284.1 million in the prior-year quarter to $260.8 million. As a percentage of sales, the metric came in at 38.7%, up from 38% reported in the year-ago quarter. Nu Skin business’ selling expenses were 41% of sales, up from 40.3% in the year-ago quarter.

General and administrative expenses of $166.6 million declined from $180.6 million in the year-ago quarter. As a percentage of sales, general and administrative expenses expanded from 24.1% to 24.7%.

Operating income of $20.3 million declined from $88.7 million in the year-ago quarter. Further, the operating margin was 3%, down from 11.9% reported in the year-ago quarter.

Segmental Results

Segment-wise, revenues (at cc) declined 26% in Mainland China, 8% in Southeast Asia/Pacific, 14% in EMEA and 6% in Japan. The same increased 4% in the Americas, 8% in South Korea and 3% in Hong Kong/Taiwan. Total Nu Skin revenues of $635.8 million fell 8% at cc from the prior-year quarter’s figure of $704.3 million.

The company benefited from 69% revenue growth in the Grow Tech business at cc. Revenues in the Manufacturing business declined 16% at cc.

Other Financial Details

Nu Skin ended the quarter with cash and cash equivalents of $339.6 million, long-term debt of $268.8 million and total stockholders' equity of $912.8 million.

During the reported quarter, the company paid out dividends of $18.9 million and repurchased $10 million worth of shares. With this, it currently has $245.4 million remaining under the current share repurchase authorization.

In a separate press release, Nu Skin announced a dividend hike. The company will now pay 38.5 cents per share, up from 38 cents paid earlier. The hiked dividend will be paid out on Mar 9, 2022, to shareholders of record as of Feb 28.


Image Source: Zacks Investment Research

Guidance

The company anticipates 2022 revenues in the range of $2.66-$2.77 billion, calling for a 1% decline to 3% growth from the year-ago period’s reported figure. The company envisions an unfavorable currency impact of 1-2% on 2022 revenues. Management expects 2022 earnings per share (EPS) in the range of $4.05-$4.45, indicating an increase of 42-56% on a reported basis. The metric is expected to fall 2-8% growth on an adjusted basis.

For first-quarter 2022, the company projects revenues of $590-$560 million that include unfavorable currency impacts of 2-3%. The projection suggests a decline of 13-17% from the year-ago quarter’s level. The Zacks Rank #4 (Sell) company’s quarterly EPS is anticipated between 75 and 65 cents, indicating an 18-28% slump from the year-ago quarter’s levels.

Nu Skin’s stock has jumped 22.7% in the past three months against the industry’s 14.6% decline.

More Consumer Staple Bets

Some other top-ranked companies are Helen of Troy Limited HELE, Inter Parfums, Inc. IPAR and United Natural Foods UNFI.

Helen of Troy, the developer and distributor of a portfolio of consumer products worldwide, currently sports a Zacks Rank #1 (Strong Buy). Shares of HELE have declined 16.4% in the past three months.

The Zacks Consensus Estimate for Helen of Troy’s current financial year’s sales and EPS suggests growth of 0.8% and 0.6%, respectively, from the year-ago period’s figures. HELE has a trailing four-quarter earnings surprise of 19.1%, on average. You can see the complete list of today’s Zacks #1 Rank stocks here.

Inter Parfums develops, manufactures and distributes prestige perfumes and cosmetics. It currently sports a Zacks Rank #1. Inter Parfums has a trailing four-quarter earnings surprise of 29.7%, on average.

The Zacks Consensus Estimate for IPAR’s current financial year sales and EPS suggests growth of 57.1% and 117.4%, respectively, from the year-ago period’s figures. Shares of the company have inched up 0.8% in the past three months.

Medifast, the manufacturer and distributor of weight loss, weight management, healthy living products and other consumable health and nutritional products, currently carries a Zacks Rank #2(Buy). Shares of Medifast have declined 16% in the past three months.

The Zacks Consensus Estimate for Medifast’s current financial year sales and EPS suggests growth of about 63% and 49.3%, respectively, from the year-ago reported figure. MED has a trailing four-quarter earnings surprise of 17.3%, on average.


7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."

Since 1988, the full list has beaten the market more than 2X over with an average gain of +25.4% per year. So be sure to give these hand-picked 7 your immediate attention. 

See them now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
United Natural Foods, Inc. (UNFI): Free Stock Analysis Report
 
Helen of Troy Limited (HELE): Free Stock Analysis Report
 
Inter Parfums, Inc. (IPAR): Free Stock Analysis Report
 
Nu Skin Enterprises, Inc. (NUS): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue